Abstract
Introduction: According to a study published in Journal of Rheumatology, the reported prevalence of secondary pulmonary hypertension (PHTN) in patients with takayasu’s arteritis (TA) varies 13.3% to 61.7% with 7 times higher risk of mortality. But the accurate US national data predicting outcomes of PHTN with TA were limited. Aims: Primary aim of our study was to identify national prevalence and outcomes of PHTN amongst patients with TA. Methods: A population-based cross-sectional study was performed in adult US hospitalizations from the nationwide inpatient sample (NIS-2016-2018). We identified patients with TA and sub-grouped into patients with and without PHTN using ICD-10 codes. Univariate analysis was performed using unpaired students’ t-test and chi-square test to identify prevalence, epidemiology, and outcomes of PHTN amongst TA patients. Mix effects multivariate survey logistic regression analyses weighted for variables were performed to identify outcomes (adjusted odds ratio [aOR] and 95% confidence interval [95%CI]) of PTHN amongst TA. p value < 0.05 was considered as significant. Results: Out of 3560 patients with TA, prevalence of PHTN was 6.04%. PHTN patients were older (58 vs 52 years-old) and highly prevalent in age group >75 years (9.3% vs 18-50 years: 3.55%), female (6.82% vs male:2.88%), Native American (40% and Asian:13.51% vs Black:6.19% vs White: 5.57%), and in emergency admissions (7% vs elective:0.89%). (p< 0.0001) Patients with PTHN had a higher frequency of mortality (4.86% vs 2.12%), morbidity (11.49% vs 5.06%), discharge to non-home (55.79% vs 33.22%), disability (81.82% vs 34.91%), and risk of mortality on discharge (69.67% vs 26.11%).(p< 0.0001) In regression analysis, we found TA as an effect modifier to PHTN for increasing odds of disability [aOR 9.10, 95%CI 3.75-22.12, p=0.0274] and risk of mortality [15.26, 6.17-37.70, p< 0.0001]. Conclusions: Poor outcomes and high disability related burden warrants early identification and risk mitigation of secondary pulmonary hypertension amongst patients with takayasu’s arteritis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.